quinacrine has been researched along with Colorectal Neoplasms in 4 studies
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Quinacrine plus a fluoropyrimidine has in vivo efficacy against metastatic colorectal cancer (mCRC)." | 9.41 | First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer. ( Astaturov, I; Cohen, SJ; Cooper, HS; Denlinger, CS; Dotan, E; El-Deiry, WS; Gallant, JN; Harvey, HA; Korzekwa, K; Kunkel, M; Lim, B; Ross, EA; Ruth, K; Sivik, J; Vijayvergia, N; Wang, EW; White, K; Winer, A; Zhou, L, 2021) |
| "5-Fluorouracil (5-FU) is an important chemotherapeutic agent for the systemic treatment of colorectal cancer (CRC), but its effectiveness against CRC is limited by increased 5-FU resistance caused by the hypoxic tumor microenvironment." | 7.91 | Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer. ( Kim, CW; Kim, HG; Lee, DH; Lee, JS; Oh, ET; Park, HJ, 2019) |
| "Quinacrine plus a fluoropyrimidine has in vivo efficacy against metastatic colorectal cancer (mCRC)." | 5.41 | First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer. ( Astaturov, I; Cohen, SJ; Cooper, HS; Denlinger, CS; Dotan, E; El-Deiry, WS; Gallant, JN; Harvey, HA; Korzekwa, K; Kunkel, M; Lim, B; Ross, EA; Ruth, K; Sivik, J; Vijayvergia, N; Wang, EW; White, K; Winer, A; Zhou, L, 2021) |
| "Colorectal cancer is the third most common malignancy in the United States." | 5.36 | Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. ( Agyeman, A; DeVecchio, J; Houghton, JA; Jani, TS; Mazumdar, T, 2010) |
| "5-Fluorouracil (5-FU) is an important chemotherapeutic agent for the systemic treatment of colorectal cancer (CRC), but its effectiveness against CRC is limited by increased 5-FU resistance caused by the hypoxic tumor microenvironment." | 3.91 | Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer. ( Kim, CW; Kim, HG; Lee, DH; Lee, JS; Oh, ET; Park, HJ, 2019) |
| "Colorectal cancer is the third most common malignancy in the United States." | 1.36 | Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. ( Agyeman, A; DeVecchio, J; Houghton, JA; Jani, TS; Mazumdar, T, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, HG | 1 |
| Kim, CW | 1 |
| Lee, DH | 1 |
| Lee, JS | 1 |
| Oh, ET | 1 |
| Park, HJ | 1 |
| Winer, A | 1 |
| Denlinger, CS | 1 |
| Vijayvergia, N | 1 |
| Cohen, SJ | 1 |
| Astaturov, I | 1 |
| Dotan, E | 1 |
| Gallant, JN | 2 |
| Wang, EW | 1 |
| Kunkel, M | 1 |
| Lim, B | 1 |
| Harvey, HA | 1 |
| Sivik, J | 1 |
| Korzekwa, K | 1 |
| Ruth, K | 1 |
| White, K | 1 |
| Cooper, HS | 1 |
| Ross, EA | 1 |
| Zhou, L | 1 |
| El-Deiry, WS | 2 |
| Jani, TS | 1 |
| DeVecchio, J | 1 |
| Mazumdar, T | 1 |
| Agyeman, A | 1 |
| Houghton, JA | 1 |
| Allen, JE | 1 |
| Smith, CD | 1 |
| Dicker, DT | 1 |
| Wang, W | 1 |
| Dolloff, NG | 1 |
| Navaraj, A | 1 |
1 trial available for quinacrine and Colorectal Neoplasms
| Article | Year |
|---|---|
First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Dru | 2021 |
3 other studies available for quinacrine and Colorectal Neoplasms
| Article | Year |
|---|---|
Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer.
Topics: Animals; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Drug Resistance, Neoplasm; | 2019 |
Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin.
Topics: Antineoplastic Agents; Carcinoma; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor | 2010 |
Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2011 |